Summit Creek Advisors LLC Takes $1.77 Million Position in TransMedics Group, Inc. $TMDX

Key Points

• Summit Creek Advisors acquired 26,707 TransMedics Group shares worth approximately $1.77 million, while institutional investors collectively own 99.67% of the stock.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above expectations, but earnings per share of $0.44 missed the $0.50 consensus estimate.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $124.18 average price target; shares recently opened at $90.69.

Summit Creek Advisors LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 26,707 shares of the company's stock, valued at approximately $1,774,000. Summit Creek Advisors LLC owned 0.08% of TransMedics Group at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of TMDX. Deutsche Bank AG bought a new stake in TransMedics Group during the second quarter worth about $14,415,000. Persistent Asset Partners Ltd purchased a new position in shares of TransMedics Group during the second quarter valued at approximately $55,000. OneDigital Investment Advisors LLC purchased a new position in shares of TransMedics Group during the second quarter valued at approximately $400,000. Flputnam Investment Management Co. bought a new stake in shares of TransMedics Group in the 2nd quarter worth approximately $77,000. Finally, Global Retirement Partners LLC bought a new stake in shares of TransMedics Group in the 2nd quarter worth approximately $450,000. 99.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company's stock, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

Shares of TMDX opened at $90.69 on Wednesday. The company has a market capitalization of $3.13 billion, a P/E ratio of 23.31 and a beta of 1.90. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm has a 50 day moving average of $76.32 and a 200 day moving average of $95.94. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to analysts' expectations of $184.00 million. During the same quarter in the previous year, the firm earned $0.92 earnings per share. TransMedics Group's revenue was up 20.7% on a year-over-year basis. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Weiss Ratings lowered TransMedics Group from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, July 28th. Zacks Research downgraded TransMedics Group from a "hold" rating to a "strong sell" rating in a report on Monday, July 6th. Stifel Nicolaus increased their target price on TransMedics Group from $75.00 to $80.00 and gave the stock a "hold" rating in a research note on Thursday, June 18th. Oppenheimer downgraded TransMedics Group from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 6th. Finally, TD Cowen reaffirmed a "buy" rating and issued a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $124.18.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source